InterPAD - DETAILS

Niraparib, 1038915-60-4, MK-4827, (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, MK4827, UNII-HMC2H89N35, MK 4827 (Base), Niraparib [USAN], HMC2H89N35, 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide, MK 4827, MK-4827 (Niraparib), ZL-2306, JNJ-64091742, 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide, CHEMBL1094636, CHEBI:176844, DTXSID50146129, Niraparib (USAN), 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide, 2H-INDAZOLE-7-CARBOXAMIDE, 2-(4-(3S)-3-PIPERIDINYLPHENYL)-, (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827, compound 56 (PMID 19873981), compound 56 [PMID 19873981], Niraparib [USAN:INN], niraparibum, 2-(4-((3S)-piperidin-3-yl)phenyl)indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-2H-indazole-7-carboxamide, 2-(4-((3S)-PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE, C19H20N4O, 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; Niraparib; Zejula; MK-4827, 3JD, Zejula (TN), NIRAPARIB [INN], NIRAPARIB [MI], MK-4827(Niraparib), NIRAPARIB [WHO-DD], GTPL8275, SCHEMBL1421875, DTXCID8068620, Niraparib(MK4827) free base?, AMY4192, EX-A290, L01XX54, MK-4827 (PARP-1), BDBM50316226, MFCD17779309, NSC754355, NSC800020, s2741, AKOS016004869, BCP9000940, CCG-267709, CS-0780, DB11793, MK-4827/MK4827, NSC-754355, NSC-800020, NCGC00346435-01, NCGC00346435-04, NCGC00346435-12, NCGC00346435-13, AC-28447, AS-35248, HY-10619, Akeega (niraparib and abiraterone acetate), BCP0726000077, 5129B, 5142B, NS00072574, D10140, EN300-7364833, A857972, Q25326660, 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]

No.	Title	Href
1	Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis. 2017;8(10):e3070. Published 2017 Oct 5. doi:10.1038/cddis.2017.471	`Click`

No.

Title

Href

Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis. 2017;8(10):e3070. Published 2017 Oct 5. doi:10.1038/cddis.2017.471

Click

Name	Niraparib
PubChem CID	24958200
Molecular Weight	320.4g/mol
Synonyms	Niraparib, 1038915-60-4, MK-4827, (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, MK4827, UNII-HMC2H89N35, MK 4827 (Base), Niraparib [USAN], HMC2H89N35, 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide, MK 4827, MK-4827 (Niraparib), ZL-2306, JNJ-64091742, 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide, CHEMBL1094636, CHEBI:176844, DTXSID50146129, Niraparib (USAN), 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide, 2H-INDAZOLE-7-CARBOXAMIDE, 2-(4-(3S)-3-PIPERIDINYLPHENYL)-, (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827, compound 56 (PMID 19873981), compound 56 [PMID 19873981], Niraparib [USAN:INN], niraparibum, 2-(4-((3S)-piperidin-3-yl)phenyl)indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-2H-indazole-7-carboxamide, 2-(4-((3S)-PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE, C19H20N4O, 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; Niraparib; Zejula; MK-4827, 3JD, Zejula (TN), NIRAPARIB [INN], NIRAPARIB [MI], MK-4827(Niraparib), NIRAPARIB [WHO-DD], GTPL8275, SCHEMBL1421875, DTXCID8068620, Niraparib(MK4827) free base?, AMY4192, EX-A290, L01XX54, MK-4827 (PARP-1), BDBM50316226, MFCD17779309, NSC754355, NSC800020, s2741, AKOS016004869, BCP9000940, CCG-267709, CS-0780, DB11793, MK-4827/MK4827, NSC-754355, NSC-800020, NCGC00346435-01, NCGC00346435-04, NCGC00346435-12, NCGC00346435-13, AC-28447, AS-35248, HY-10619, Akeega (niraparib and abiraterone acetate), BCP0726000077, 5129B, 5142B, NS00072574, D10140, EN300-7364833, A857972, Q25326660, 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]
Drug Type	Small molecule
Formula	C₁₉H₂₀N₄O
SMILES	C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
InChI	1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
InChIKey	PCHKPVIQAHNQLW-CQSZACIVSA-N
CAS Number	1038915-60-4
ChEMBL ID	CHEMBL1094636
ChEBI ID	CHEBI:176844
TTD ID	D0DN0W
Drug Bank ID	DB11793
KEGG ID	D10140
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Berberine, Niraparib
Partner Name	Berberine
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Up-regulation	Phosphorylation	H2AX	hsa3014
	Down-regulation	Expression	NR1H4	KEGG ID N.A.
	Down-regulation	Expression	RAD51	hsa5888
In Vitro Model	A2780	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_0134
In Vitro Model	HO-8910	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_6868
In Vivo Model	The animals were subcutaneously inoculated with 1 × 106 A2780 cells (suspended in 100 μl PBS) and six days later the tumor-bearing mice were randomly divided into four groups and were then treated daily by oral gavage with vehicle (sodium carboxymethycellulose, SCMC), berberine (200 mg/kg bodyweight), niraparib (40 mg/kg bodyweight) and berberine (200 mg/kg) in combination with niraparib (40 mg/kg), respectively, for 15 days.
Result	The results indicate that by inducing oxidative DNA damage and downregulating HRR in cancer cells berberine is able to further sensitize cancer cells to PARP inhibition. These results demonstrate a potential therapeutic value of combined application of berberine and PARP inhibitors in ovarian cancer treatment.